Transgenic Rat Model for Cerebral Amyloid Angiopathy

This novel rat model for CAA and Alzheimer's has distinct advantages over the mouse models and provides an invaluable platform to investigate therapeutic strategies effective bio-markers Background: Transgenic mouse models, such as Tg-SwDI, have provided a useful paradigm to investigate the contribution of small vessel cerebral amyloid angiopathy (CAA) to neuro-inflammation, vascular cognitive impairment & dementia (VCID) and Alzheimer's. However, mouse models have obvious shortcomings with regards to sophisticated cognitive testing and structural neuro-imaging. Therefore, more appropriate animal models of small vessel CAA are necessary to move the field forward towards understanding the pathogenesis and its contribution to structural changes in the brain and VCID. Technology Overview: Dr. William Van Nostrand at Stony Brook University has developed a transgenic rat model for CAA, which is a significant improvement over the existing mouse models. These novel transgenic rats provide an important advanced model and help to elucidate how pathological processes of CAA, Alzheimer?s and dementia evolve and provide a means to develop and test biomarkers and therapeutic agents that can prevent this disease. Advantages: Provides a more suited animal model for CAA, dementia Alzheimer?s pathology and progression Useful for testing novel compounds and treatment strategies Applications: Rat Model Research tool Therapeutic Screening Drug delivery Intellectual Property Summary: Stage of Development: Rate model available Licensing Potential: We seek to develop and commercialize, by an exclusive or non-exclusive license agreement with a company active in the area Licensing Status: Available for License Additional Information: rat model, CAA, Alzheimer's, dementia
Patent Information:
Technology/Start-up ID: